UPDATED: Amicus shares slammed as lead PhIII drug fails a key head-to-head test for Pompe disease — but the CEO still projects an FDA OK and bright future
Amicus stock got hammered Thursday afternoon after the biotech put out word that the crown jewel in the pipeline just failed the primary endpoint in a head-to-head study with the standard of care for Pompe disease.
CEO John Crowley, though, has a long track record at spotlighting the positive, which was on full display in its statement on the failed study. Researchers for the company highlighted some marginally positive secondary data with an improvement in respiratory function from a post hoc analysis that they plan to roll ahead to the FDA.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 102,900+ biopharma pros reading Endpoints daily — and it's free.